LeonaBio
Bothell, Washington, United StatesSee on the mapFounded 2011
- Series B
- ALS
LeonaBio is a biotechnology company developing novel therapeutics for diseases with high unmet medical needs, including neurological diseases such as amyotrophic lateral sclerosis (ALS) and treatment-resistant metastatic breast cancer. Its research emphasizes neuronal health and therapies intended to restore and maintain cellular connections.
- RaisedTotal raised
- $807M
- Jun 2020Latest priced round, Jun 2020
- Series B
- Investors
- 35
- Founded
- 2011
- Employees
- 51–200
reccy insights
That financing followed a $103.5 million post-IPO equity round dated Jan 20, 2021. The company’s stated research focus spans neurological disease and oncology, including ALS and treatment-resistant metastatic breast cancer. Its therapeutic approach emphasizes neuronal health and restoring cellular connections; the structured company description also identifies ATH-1020 as a candidate designed to enhance the neurotrophic HGF system. The company-name information is inconsistent: LeonaBio is associated with the Bothell business identity, while another company name appears in company details. The financing and research details should therefore be read with that identity discrepancy in mind.
Written by reccy's AI from company sites, press and funding records · updated Nov 2026
What makes LeonaBio distinct
- 01Pursues therapies for high-unmet-need conditions across neurological disease and oncology.
- 02Centers its therapeutic research on neuronal health and restoring cellular connections.
- 03Identifies ALS and treatment-resistant metastatic breast cancer among its areas of focus.
- 04Describes a patient-centered, collaborative culture emphasizing inclusion, integrity, and innovation.
Technology & products
- ATH-1020
A drug candidate designed to enhance the neurotrophic HGF system to support neuronal health and function.
- Research focused on neuronal health and restoring cellular connections.
- ATH-1020 is designed to enhance the neurotrophic HGF system.
- Exploration of early compounds directed at novel targets for clinical applications.
Research roots1
Labs and research groups this company came from or works with.
- No page yetWashington State UniversityPullman, United StatesPullman, United States · No page yetLicence
Funding
- Post-IPO EquityDec 2025$90MLed by TCGX, Perceptive Advisors, Commodore Capital LP, Commodore, TCG Crossover
- Post-IPO EquityJan 2021$104MLed by TCGX, Perceptive Advisors, Commodore Capital LP
- GrantDec 2020
Investors11
- TCGX
- Bruce Montgomery
- Michael Montgomery
- Ditch Plains Capital Management
About LeonaBio
- Products
- ATH-1020
- Leadership
- Leen KawasLewis RumplerJoseph Harding
- Focus areas
- Biotechnology, therapeutics, pharmaceuticals, neurology, oncology, neuroscience, drug discovery, ALS
- Headquarters
- Bothell, Washington, United States
- Founded
- 2011
- Employees
- 51–200
- Status
- Active · public company